Knockdown of the Epidermal Growth Factor Receptor Gene to Investigate Its Therapeutic Potential for the Treatment of Non-small-cell Lung Cancers
Overview
Pulmonary Medicine
Authors
Affiliations
Background: Epidermal growth factor receptor (EGFR) is often overexpressed in non-small-cell lung cancer (NSCLC). Anti-EGFR agents, including EGFR-tyrosine kinase inhibitors are considered to be effective when a drug-sensitive EGFR mutation is present. However, inherent and acquired resistances are major problems of EGFR-targeting therapies. In this study, we performed EGFR knockdown by using small interfering RNAs in NSCLC cell lines to examine the significance of targeting EGFR for NSCLC therapy.
Methods: We treated 13 NSCLC cell lines, including 8 EGFR mutant and 5 EGFR wild type by using gefitinib or small interfering RNAs against EGFR (siEGFR). Three cell lines (PC-9-GR1, RPC-9, and HCC827-ER) were experimentally established with acquired resistance to EGFR-tyrosine kinase inhibitors. The antitumor effect was determined by using an 3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt (MTS) or colony formation assay. The protein expression was evaluated by using Western blotting.
Results: All 13 cell lines expressed EGFR protein, and siEGFR downregulated EGFR protein expression in all. The cell viability was suppressed by siEGFR in 6 of 8 EGFR-mutant cell lines (suppressed 57%-92% of control cells), including PC-9-GR1 and RPC-9. The NCI-H1650 and HCC827-ER harbored EGFR mutations but were not suppressed. Of note, PTEN (phosphatase and tensin homolog) was deleted in NCI-H1650, and c-MET was amplified in HCC827-ER. It was not suppressed in any of the EGFR wild-type cells except in the NCI-H411, in which EGFR is phosphorylated, which indicates its activation.
Conclusions: Analysis of the results indicated that EGFR can be a therapeutic target in NSCLCs with EGFR activation. In contrast, targeting EGFR is not appropriate for tumors in which EGFR is not activated, even if EGFR is expressed.
EGFR is a potential dual molecular target for cancer and Alzheimer's disease.
Choi H, Jeong Y, Kim J, Hoe H Front Pharmacol. 2023; 14:1238639.
PMID: 37601068 PMC: 10433764. DOI: 10.3389/fphar.2023.1238639.
Li Q, Wang Y, He J J Clin Lab Anal. 2021; 35(7):e23853.
PMID: 34057242 PMC: 8274984. DOI: 10.1002/jcla.23853.
Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.
Yoshioka T, Shien K, Takeda T, Takahashi Y, Kurihara E, Ogoshi Y Cancer Sci. 2019; 110(8):2549-2557.
PMID: 31162771 PMC: 6676122. DOI: 10.1111/cas.14089.
Liu Y, Jiang H, Zhou H, Ying X, Wang Z, Yang Y Oncol Lett. 2018; 15(3):2829-2838.
PMID: 29467862 PMC: 5778865. DOI: 10.3892/ol.2017.7656.
Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.
Yoshioka T, Shien K, Namba K, Torigoe H, Sato H, Tomida S Cancer Sci. 2018; 109(4):1166-1176.
PMID: 29465762 PMC: 5891184. DOI: 10.1111/cas.13546.